Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.